• 1
    Alessi CA, Henderson CT. Constipation and fecal impaction in the long-term care patient. Clin Geriatr Med 1988; 4: 57188.
  • 2
    Williams SG, DiPalma JA. Constipation in the long-term care facility. Soc Gastroenterol Nurs 1990; 12: 17982.
  • 3
    Merkus JWFM. Constipation in the elderly. II. Prevalence and causes of laxative use and experience with bulk laxatives and lactulose in geriatric patients. T Gerontol Geriatr 1984; 15: 1514.
  • 4
    Bouras EP, Camilleri M, Burton DD, McKinzie S. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut 1999; 44: 6826.
  • 5
    De Schryver AM, Andriesse GI, Samsom M, Smout AJ, Gooszen HG, Akkermans LM. The effects of the specific 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteers. Aliment Pharmacol Ther 2002; 16: 60312.
  • 6
    De Maeyer JH, Lefebvre RA, Schuurkes JA. 5-HT (4) receptor agonists: similar but not the same. Neurogastroenterol Motil 2008; 20: 99112.
  • 7
    Bouras EP, Camilleri M, Burton DD, Thomforde G, McKinzie S, Zinsmeister AR. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001; 120: 35460.
  • 8
    Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008; 358: 234454.
  • 9
    Coremans G, Kerstens R, De Pauw M, Stevens M. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial. Digestion 2003; 67: 829.
  • 10
    Emmanuel AV, Roy AJ, Nicholls TJ, Kamm MA. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther 2002; 16: 134756.
  • 11
    Mueller-Lissner SA, Rykx A, Kerstens R, Vandeplassche L. Randomized double-blind placebo-controlled trial to evaluate efficacy and safety of prucalopride (Resolor®) in elderly patients with chronic constipation [Abstract no 1052]. Gastroenterology 2008; 134: A-157.
  • 12
    Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation – a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009; 29: 31528.
  • 13
    Tack J, Van Outryve M, Beyens G, Kerstens R, Vandeplassche L. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009; 58: 35765.
  • 14
    Drolet B, Khalifa M, Daleau P, Hamelin BA, Turgeon J. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation 1998; 97: 20410.
  • 15
    Kii Y, Ito T. Effects of 5-HT4-receptor agonists, cisapride, mosapride citrate, and zacopride, on cardiac action potentials in guinea pig isolated papillary muscles. J Cardiovasc Pharmacol 1997; 29: 6705.
  • 16
    Mohammad S, Zhou Z, Gong Q, January CT. Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol 1997; 273: H25348.
  • 17
    Tonini M, De Ponti F, Di Nucci A, Crema F. Review article: cardiac adverse effects of gastrointestinal prokinetics. Aliment Pharmacol Ther 1999; 13: 158591.
  • 18
    Tooley PJ, Vervaet P, Wager E. Cardiac arrhythmias reported during treatment with cisapride. Pharmacoepidemiol Drug Saf 1999; 8: 578.
  • 19
    Anderson JL, May HT, Blair TL, Muhlestein JB, Horne BD, Carlquist JF. Association of tegaserod with cardiovascular outcomes in a matched study of 18,221 treated and untreated patients. Eur Heart J 2008; 29(Suppl): 755.
  • 20
    Busti AJ, Murillo JR Jr, Cryer B. Tegaserod-induced myocardial infarction: case report and hypothesis. Pharmacotherapy 2004; 24: 52631.
  • 21
    Pfannkuche HJ, Dennis E. Tegaserod-induced myocardial infarction: case report and hypothesis – an alternative viewpoint. Pharmacotherapy 2004; 24: 164950. discussion 1650-1641.
  • 22
    Thompson C. Novartis suspends tegaserod sales at FDA’s request. Am J Health Syst Pharm 2007; 64: 1020.
  • 23
    Van Outryve MV, Beyens G, Kerstens R, Vandeplassche L. Long-term follow up study of oral prucalopride (Resolor) administered to patients with chronic constipation. Gastroenterology 2008; 134: A-547.
  • 24
    Van De Velde V, Ausma J, Vandeplassche L. Pharmacokinetics of prucalopride (Resolor) in man. Gut 2008; 57: A282.
  • 25
    European Medicines Agency. CPMP/986/96. The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. December 1997.
  • 26
    Morganroth J. Risk factors for the development of proarrhythmic events. Am J Cardiol 1987; 59: 32E7E.
  • 27
    Garson A Jr. How to measure the QT interval – what is normal? Am J Cardiol 1993; 72: 14B6B.
  • 28
    Browne KF, Prystowsky EN, Heger JJ, Cerimele BJ, Fineberg N, Zipes DP. Prolongation of the QT interval induced by probucol: demonstration of a method for determining QT interval change induced by a drug. Am Heart J 1984; 107: 6804.
  • 29
    Molnar J, Zhang F, Weiss J, Ehlert FA, Rosenthal JE. Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events. J Am Coll Cardiol 1996; 27: 7683.
  • 30
    Morganroth J, Brozovich FV, McDonald JT, Jacobs RA. Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol 1991; 67: 7746.
  • 31
    Chapman H, Pasternack M. The action of the novel gastrointestinal prokinetic prucalopride on the HERG K+ channel and the common T897 polymorph. Eur J Pharmacol 2007; 554: 98105.
  • 32
    Potet F, Bouyssou T, Escande D, Baro I. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-a-gogo K+ channel. J Pharmacol Exp Ther 2001; 299: 100712.
  • 33
    De Maeyer JH, Schuurkes JA, Lefebvre RA. Selective desensitization of the 5-HT4 receptor-mediated response in pig atrium but not in stomach. Br J Pharmacol 2009; 156: 36276.
  • 34
    Emmanuel AV, Kamm MA, Roy AJ, Antonelli K. Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers. Gut 1998; 42: 5116.
  • 35
    Boyce M, Kerstens R, Beyens G, Ausma J, Vandeplassche L. Cardiovascular safety of prucalopride in healthy subjects: results from two randomized, double-blind, placebo-controlled, cross-over trials. Gastroenterology 2009; 136: T1265.
  • 36
    Camilleri M, Beyens G, Kerstens R, Vandeplassche L. Long-term follow-up of safety and satisfaction with bowel function in response to oral prucalopride in patients with chronic constipation. Gastroenterology 2009; 136: 160.